Sign in Sign up for free

Last updated: 24 May 2024 at 5:15pm EST

Alan Fuhrman Net Worth



Mr. Fuhrman SWTX stock SEC Form 4 insiders trading

Alan has made over 1 trades of the SpringWorks Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 2,625 units of SWTX stock worth $29,794 on 8 June 2018.

The largest trade he's ever made was exercising 2,625 units of SpringWorks Therapeutics stock on 8 June 2018 worth over $29,794. On average, Alan trades about 125 units every 0 days since 2016. As of 8 June 2018 he still owns at least 2,625 units of SpringWorks Therapeutics stock.

You can see the complete history of Mr. Fuhrman stock trades at the bottom of the page.





Alan Fuhrman biography

Alan Fuhrman CPA serves as Independent Director of the Company. Mr. Fuhrman has served as chief financial officer of Amplyx Pharmaceuticals, Inc. Prior to Amplyx, Mr. Fuhrman served as chief financial officer of Mirna Therapeutics, Inc. from September 2015 to August 2017. Mr. Fuhrman also served as chief financial officer of Ambit Biosciences Corporation from October 2010 to November 2014, chief financial officer of Naviscan, Inc. from November 2008 to September 2010 and chief financial officer of Sonus Pharmaceuticals, Inc. from September 2004 to August 2008. Mr. Fuhrman has served on the board of directors of Checkmate Pharmaceuticals, Inc. since June 2019 and as a member of the board of directors and chairman of the audit committee of Loxo Oncology, Inc. from January 2015 to February 2019. Mr. Fuhrman received B.S. degrees in business administration and agricultural economics from Montana State University and practiced as a CPA with Coopers and Lybrand.

What is the salary of Alan Fuhrman?

As the Independent Director of SpringWorks Therapeutics, the total compensation of Alan Fuhrman at SpringWorks Therapeutics is $339,617. There are 14 executives at SpringWorks Therapeutics getting paid more, with Saqib Islam having the highest compensation of $3,284,920.



How old is Alan Fuhrman?

Alan Fuhrman is 63, he's been the Independent Director of SpringWorks Therapeutics since 2019. There are 3 older and 15 younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics, Inc. is Freda Lewis-Hall, 65, who is the Independent Director.

What's Alan Fuhrman's mailing address?

Alan's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108.

Insiders trading at SpringWorks Therapeutics

Over the last 6 years, insiders at SpringWorks Therapeutics have traded over $386,249,433 worth of SpringWorks Therapeutics stock and bought 800,000 units worth $14,400,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Capital Life Sciences Inves..., and Jeffrey Lawrence Schwartz. On average, SpringWorks Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $6,795,384. The most recent stock trade was executed by Saqib Islam on 3 September 2024, trading 49,000 units of SWTX stock currently worth $1,987,930.



What does SpringWorks Therapeutics do?

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.



What does SpringWorks Therapeutics's logo look like?

SpringWorks Therapeutics, Inc. logo

SpringWorks Therapeutics executives and stock owners

SpringWorks Therapeutics executives and other stock owners filed with the SEC include: